Palatnik A, Frolov K, Fux M, Benjamin J (2001). "Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder". Journal of Clinical Psychopharmacology21 (3): 335–339. PMID11386498. doi:10.1097/00004714-200106000-00014.
Taylor MJ, Wilder H, Bhagwagar Z, Geddes J (2004). Taylor, Matthew J, ed. "Inositol for depressive disorders". Cochrane Database Syst Rev (2): CD004049. PMID15106232. doi:10.1002/14651858.CD004049.pub2.
Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G (1999). "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome". N Engl J Med340 (17): 1314–1320. PMID10219066. doi:10.1056/NEJM199904293401703.
Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, DiBenedetto A, D’Anna R (2011). "Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study". Menopause: The Journal of The North American Menopause Society18 (1): 102–104. doi:10.1097/gme.0b013e3181e8e1b1.
Silver SM, Schroeder BM, Sterns RH, Rojiani AM (2006). "Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats". J Neuropathol Exp Neurol65 (1): 37–44. PMID16410747. doi:10.1097/01.jnen.0000195938.02292.39.
Palatnik A, Frolov K, Fux M, Benjamin J (2001). "Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder". Journal of Clinical Psychopharmacology21 (3): 335–339. PMID11386498. doi:10.1097/00004714-200106000-00014.
Taylor MJ, Wilder H, Bhagwagar Z, Geddes J (2004). Taylor, Matthew J, ed. "Inositol for depressive disorders". Cochrane Database Syst Rev (2): CD004049. PMID15106232. doi:10.1002/14651858.CD004049.pub2.
Silverstone, P. H.; McGrath, B. M.; Kim, H. (2005). "Bipolar disorder and myo-inositol: A review of the magnetic resonance spectroscopy findings". Bipolar Disorders 7 (1): 1–10. doi:10.1111/j.1399-5618.2004.00174.x. PMID 15654927.
Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G (1999). "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome". N Engl J Med340 (17): 1314–1320. PMID10219066. doi:10.1056/NEJM199904293401703.
Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E (2002). "Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome". Endocr Pract8 (6): 417–423. PMID15251831.
Nestler J E, Jakubowicz D J, Iuorno M J (2000). "Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome". J Pediatr Endocrinol Metab. 13 Suppl 5: 1295–1298. PMID11117673.
Silver SM, Schroeder BM, Sterns RH, Rojiani AM (2006). "Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats". J Neuropathol Exp Neurol65 (1): 37–44. PMID16410747. doi:10.1097/01.jnen.0000195938.02292.39.
Vucenik, I; Shamsuddin, AM (2003). "Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic.". The Journal of nutrition133 (11 Suppl 1): 3778S–3784S. PMID14608114.